Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…